Clinical prospects for new thyroid hormone analogues

Current Opinion in Endocrinology and Diabetes

Volumn 12, Issue 5, 2005, Pages 363-370

  Ocasio, Cory A ^a   Scanlan, Thomas S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiac sparing; Hypercholesterolemia; Isoform specific; Liver selective; Thyroid hormone analogues; Thyroid hormone receptor; Thyromimetics

Indexed keywords

3,5 DIIODOTHYROPROPIONIC ACID; CAPTOPRIL; CGS 23425; DEBUTYLDRONEDARONE; DRONEDARONE; GC 1; GC 24; KAT 681; KB 141; NH 3; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR; THYROMIMETIC AGENT; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DRUG MECHANISM; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART OUTPUT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTHYROIDISM; KNOCKOUT MOUSE; LIVER CARCINOGENESIS; NONHUMAN; OBESITY; REVIEW; TISSUE SPECIFICITY;

EID: 26444526576     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000177422.57988.b2     Document Type: Review

References (78)

1. Scanlan T, Yoshihara H, Nguyen N-H, Chiellini G. Selective thyromimetics: tissue-selective thyroid hormone analogs. Curr Opin Drug Discov Devel 2001; 4:614-622.
2. Baxter J, Dillmann W, West B, et al. Selective modulation of thyroid hormone receptor action. J Steroid Biochem Mol Biol 2001; 76:31-42.
3. Yoshihara H, Apriletti J, Baxter J, Scanlan T. Structural determinants of selective thyromimetics. J Med Chem 2003; 46:3152-3161.
4. Greenspan F, Gardner D. The thyroid gland. In: Greenspan F, editor. Basic and clinical endocrinology, 6th ed. New York: McGraw-Hill; 2001. pp. 201-272.
5. Yen P. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001; 81:1097-1142.
6. Utiger R. The thyroid: physiology, thyrotoxicosis, hypothyroidism, and the painful thyroid. In: Felig P, Frohman L, editors. Endocrinology and metabolism, 4th ed. New York: McGraw-Hill; 2001. pp. 261-347.
7. Franklin J. Metabolic changes in thyrotoxicosis. In: Braverman L, Utiger R, editors. Werner & Ingbar's the thyroid: a fundamental and clinical text, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 667-672.
8. Malloy M, Kane J. Agents used in hyperlipidemia. In: Katzung B, editor. Basic and clinical pharmacology, 8th ed. New York: McGraw Hill; 2001. pp. 581-595.
9. Ness G, Lopez D, Chambers C, et al. Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression. Biochem Pharmacol 1998; 56:121-129.
10. Kahaly G, Dillman W. Thyroid hormone action in the heart. Endocr Rev 2005. [Epub ahead of print].
11. Woeber K. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94-98.
12. Danzi S, Klein I. Thyroid hormone-regulated cardiac gene expression and cardiovascular disease. Thyroid 2002; 12:467-472.
13. De K, Gosh G, Datta M, et al. Analysis of differentially expressed genes in hyperthyroid-induced hypertrophied heart by cDNA microarray. J Endocrinol 2004; 182:303-314.
14. Fadel B, Ellahham S, Ringel M, et al. Hyperthyroid heart disease. Clin Cardiol 2000; 23:402-408.
15. Morkin E, Ladenson P, Goldman S, Adamson C. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present, and future prospects. J Mol Cell Cardiol 2004; 37:1137-1146. Presents a chronology on thyromimetic development, going back as far as the 1950s. The potential of selected TRβ-selective thyromimetics and DITPA in treating hypercholesterolemia and heart failure is discussed as well.
16. Underwood A, Emmett J, Ellis E, et al. A thyromimetic that decreases plasma cholesterol levels without increasing cardiac activity. Nature 1986; 324:425-429.
17. Bianco A, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002; 23:38-89.
18. Weinberger C, Thompson C, Ong E, et al. The c-erb-A gene encodes a thyroid hormone receptor. Nature 1986; 324:641-646.
19. Sap J, Muñoz A, Damm K, et al. The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 1986; 324:635-639.
20. Harvey C, Williams G. Mechanism of thyroid hormone action. Thyroid 2002; 12:441-446.
21. Zhang J, Lazar M. The mechanism of action of thyroid hormones. Annu Rev Physiol 2000; 62:439-466.
22. Ribeiro R, Apriletti J, Wagner R, et al. X-ray crystallographic and functional studies of thyroid hormone receptor. J Steroid Biochem Mol Biol 1998; 65:133-141.
23. Weatherman R, Fletterick R, Scanlan T. Nuclear-receptor ligands and ligand-binding domains. Annu Rev Biochem 1999; 68:559-581.
24. Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001; 81:1269-1303.
25. Glass C. Some new twists in the regulation of gene expression by thyroid hormone and retinoic acid receptors. J Endocrinol 1996; 150:349-357.
26. Rastinejad F. Structure and function of the steroid and nuclear receptor DNA binding domain. In: Freedman L, editor. Molecular biology of steroid and nuclear hormone receptors. Boston: Birkhauser; 1998. pp. 105-131.
27. Rosenfeld M, Glass C. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 2001; 276:36865-36868.
28. Robyr D, Wolffe A, Wahli W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol Endocrinol 2000; 14:329-347.
29. Shibusawa N, Hollenberg A, Wondisford F. Thyroid hormone receptor DNA binding is required for both positive and negative gene regulation. J Biol Chem 2003; 278:732-738.
30. Ribeiro R, Feng W, Wagner R, et al. Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor. J Biol Chem 2001; 276:14987-14995.
31. Robinson-Rechavi M, Carpentier A-S, Duffraisse M, Laudet V. How many nuclear receptors are there in the human genome? Trends Genet 2001; 17:554-556.
32. Evans R. The steroid and thyroid hormone receptor superfamily. Science 1988; 240:889-895.
33. Lazar M. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 1993; 14:184-193.
34. Brent G. Tissue-specific actions of thyroid hormone: insights from animal models. Rev Endocr Metab Disord 2000; 1:27-33.
35. Yen P. Molecular basis of resistance to thyroid hormone. Trends Endocrinol Metab 2003; 14:327-333.
36. Suzuki H, Cheng S-Y. Compensatory role of thyroid hormone receptor TRα1 in resistance to thyroid hormone: study in mice with a targeted mutation in the TRβ gene and deficient in TRα1. Mol Endocrinol 2003; 17:1647-1655.
37. Flamant F, Samarut J. Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. Trends Endocrinol Metab 2003; 14:85-90.
38. 1 has selective actions in bone development, particularly on bone ossification, and shows that the TRβ-selective agonists can not reverse all of the negative effects of hypothyroidism on skeletal maturation.
39. Mai W, Janier M, Allioli N, et al. Thyroid hormone receptor α is a molecular switch of cardiac function between fetal and postnatal life. Proc Natl Acad Sci U S A 2004; 101:10332-10337.
40. Swanson E, Gloss B, Belke D, et al. Cardiac expression and function of thyroid hormone receptor β and its PV mutant. Endocrinology 2003; 144:4820-4825.
41. Ortiga-Carvalho T, Hashimoto K, Pazos-Moura C, et al. Thyroid hormone resistance in the heart: role of the thyroid hormone receptor β isoform. Endocrinology 2004; 145:1625-1633. The authors demonstrate that TRβ has little effect on cardiac function, with the exception of inducing cardiac hypertrophy.
42. Weiss R, Korcarz C, Chassande O, et al. Thyroid hormone and cardiac function in mice deficient in thyroid hormone receptor-α or -β: an echocardiograph study. Am J Physiol Endocrinol Metab 2002; 283:E428-E435.
43. Gullberg H, Rudling M, Saltó C, et al. Requirement for thyroid hormone receptor β in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol 2002; 16:1767-1777.
44. Yen P, Feng X, Flamant F, et al. Effects of ligand and thyroid hormone receptor isoforms on hepatic gene expression profiles of thyroid hormone receptor knockout mice. EMBO Rep 2003; 4:581-587.
45. Shwartz H, Trence D, Oppenheimer J, et al. Distribution and metabolism of L- and D-triiodothyronine (T3) in the rat: preferential accumulation of L-T3 by hepatic and cardiac nuclei as a probable explanation of the differential biological potency of T3 enantiomers. Endocrinology 1983; 113:1236-1243.
46. Ichikawa K, Miyamoto T, Kakizawa T, et al. Mechanism of liver-selective thyromimetic activity of SK&F L-94901: evidence for the presence of a cell-type-specific nuclear iodothyronine transport process. J Endocrinol 2000; 165:391-397.
47. Baxter J, Webb P, Grover G, Scanlan T. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab 2004; 15:154-157. Describes the development of a highly potent TRβ-selective agonist, GC-1. The authors also compare the efficacies of GC-1 and atorvastatin, a 'statin' in the hydroxymethylglutaryl coenzyme A reductase inhibitor family of cholesterol-lowering drugs, and show that GC-1 is more effective at lowering cholesterol (about two-fold to threefold more effective).
48. Hennemann G, Docter R, Friesma E, et al. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev 2001; 22:451-476.
49. Fujiwara K, Adachi H, Nishio T, et al. Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology 2001; 142:2005-2012.
50. 3 and differentially regulated by thyromimetics with different tissue profiles, DITPA and CGS-23425.
51. Morkin E, Pennock G, Spooner P, et al. Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analog, in heart failure. Thyroid 2002; 6:527-533.
52. Tomanek R, Zimmerman M, Suvarna P, et al. A thyroid hormone analog stimulates angiogenesis in the post-infarcted rat heart. J Mol Cell Cardiol 1998; 30:923-932.
53. Zheng W, Weiss R, Wang X, et al. DITPA stimulates arteriolar growth and modifies myocardial postinfarction remodeling. Am J Physiol Heart Circ Physiol 2004; 286:H1994-2000. This study shows that DITPA facilitates arteriolar growth, modifies ventricular remodeling, and limits infarct expansion and thus may be useful in treating patients who have had a myocardial infarction.
54. Wang X, Zheng W, Christensen L, Tomanek R. DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am J Physiol Heart Circ Physiol 2003; 284:613-618.
55. Spooner P, Thai H, Goldman S, Gaballa M. Thyroid hormone analog, DITPA, improves endothelial nitric oxide and beta-adrenergic mediated vasorelaxation after myocardial infarction. J Cardiovasc Pharmacol 2004; 44:453-459. This study investigates the effects of DITPA on endothelial function after a myocardial infarction, with particular emphasis on endothelial nitric oxide and β-adrenergic receptor-mediated vasorelaxation. The authors provide evidence showing that DITPA improves impaired β-adrenergic receptor-mediated vasorelaxation by a nitric oxide-dependent mechanism.
56. van Beeren H, Jong W, Kaptein E, et al. Dronedarone acts as a selective inhibitor of 3,5,3′-triiodothyronine binding to thyroid hormone receptor-α1: in vitro and in vivo evidence. Endocrinology 2003; 144:552-558.
57. van Beeren H, Bakker O, Wiersinga W. Structure-function relationship of the inhibition of the 3,5,3′-triiodothyronine binding to the α1- and β1-thyroid hormone receptor by amiodarone analogs. Endocrinology 1996; 137:2807-2814.
58. Pantos C, Mourouzis I, Malliopoulou V, et al. Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor α1. Thyroid 2005; 15:16-22. Dronedarone recapitulates the cardioprotective effects of hypothyroidism on the hearts of hypothyroid rats subjected to ischemia. Dronedarone also had the unexpected property of inducing appetite suppression, which subsequently caused weight loss, possibly by antagonizing TRα in the hypothalamus.
59. Chiellini G, Apriletti J, Yoshihara H, et al. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 1998; 5:299-306.
60. Trost S, Swanson E, Gloss B, et al. The thyroid hormone receptor-β-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000; 141:3057-3064.
61. Wagner R, Hubber B, Shiau A, et al. Hormone selectivity in thyroid hormone receptors. Mol Endocrinol 2001; 15:398-410.
62. 3. Also, GC-1 treatment in primates causes a reduction in body weight (∼4%) after 7 days of treatment.
63. Ye L, Li Y-L, Mellstrom K, et al. Thyroid receptor ligands. 1. agonist ligands selective for the thyroid receptor β1. J Med Chem 2003; 46:1580-1588.
64. Grover G, Mellstrom K, Ye L, et al. Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A 2003; 100:10067-10072.
65. Borngraeber S, Budny M-J, Chiellini G, et al. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc Natl Acad Sci U S A 2003; 100:15358-15363.
66. Hangeland J, Doweyko A, Dejneka T, et al. Thyroid receptor ligands: part 2: thyromimetics with improved selectivity for the thyroid hormone receptor beta. Bioorg Med Chem Lett 2004; 14:3549-3553. Karo Bio (Huddinge, Sweden) explores the effects of bulky lipophilic substituents at position 3 of two scaffolds; one scaffold is KB-141 and the other differs from KB-141 in that the inner-ring chlorides are replaced with bromides. From this study, the most potent and selective compounds were derived from KB-141 and contained a 3′-phenyl group.
67. Taylor A, Stephan Z, Steele R, Wong N. Beneficial effects of a novel thyromimetic on lipoprotein metabolism. Mol Pharmacol 1997; 52:542-547.
68. Hayashi M, Ohnota H, Tamura T, et al. Inhibitory effects of KAT-681, a liver-selective thyromimetic, on development of hepatocellular proliferative lesions in rats induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Arch Toxicol 2004; 78:460-466. This is the first report to implicate a selective thyromimetic (KAT-681) as a chemopreventive agent.
69. Hayashi M, Tamura T, Kuroda J, et al. Different inhibitory effects in the early and late phase of treatment with KAT-681, a liver-selective thyromimetic, on rat hepatocarcinogenesis induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Toxicol Sci 2005; 84:22-28. This study explores the antihepatocarcinogenic effects of KAT-681 on hepatocellular proliferative lesions. Long-term KAT treatment reduced the mean size of hepatocellular adenomas as well as reducing the mean size and number of altered hepatocellular foci.
70. Shiohara H, Nakamura T, Kikuchi N, et al., for Kissei Pharmaceutical Co. (Matsumoto City, Japan). Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof. Eur. Pat. Appl. EP-1471049A1; 2004. This patent reports the cholesterol-lowering effects of TRβ-selective thyromimetics with an inner indan ring. Two highly selective TRβ-selective agonists potently reduce serum cholesterol with median effective dose values of 37 and 300 nmol/kg.
71. Malm J, Koehler K, Garcia-Collard AM, et al., for Karo Bio (Huddinge, Sweden). Preparation of indole derivatives as new thyroid receptor agonist ligands and methods of use. PCT Int. Appl. WO-2004018421; 4 Aug 2004.
72. Dow R, Schneider S, Paight E, et al. Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TRβ subtype-selective thyromimetics. Bioorg Med Chem Lett 2003; 13:379-382.
73. Webb P, Nguyen N-H, Chiellini G, et al. Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol 2003; 83:59-73.
74. Nguyen N-H, Apriletti J, Cunha-Lima S, et al. Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 2002; 45:3310-3320.
75. Yoshihara H, Apriletti J, Baxter J, Scanlan T. A designed antagonist of the thyroid hormone receptor. Bioorg Med Chem Lett 2001; 11:2821-2825.
76. Chiellini G, Nguyen N-H, Apriletti J, et al. Synthesis and biological activity of novel thyroid hormone analogues: 5′-aryl substituted GC-1 derivatives. Bioorg Med Chem Lett 2002; 10:333-346.
77. 3.
78. Lim W, Nguyen N-H, Yang HY, et al. A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J Biol Chem 2002; 277:35664-35670.